Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Hemagglutinin (HA) is a major surface glycoprotein of the influenza B virus (Victoria lineage) and plays a critical role in viral entry into host cells. It is also the primary target for neutralizing antibodies, making it central to immune recognition and vaccine design. The Victoria lineage is antigenically distinct from the Yamagata lineage, necessitating the inclusion of both in seasonal influenza vaccines. HA mediates viral attachment to sialic acid receptors on host cells and subsequent fusion of the viral and host cell membranes.
Vaccines: Induce neutralizing antibodies that prevent viral attachment and entry. Monoclonal antibodies: Bind to HA and prevent fusion.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hemagglutinin of Influenza B virus (Victoria lineage).